RARE Daily

Conrad Prebys Foundation Awards $300,000 Grant to n-Lorem

March 21, 2022

The Conrad Prebys Foundation has awarded a one year $300,000 grant to the nonprofit n-Lorem Foundation that will support the organization’s discovery and development efforts to provide personalized experimental antisense oligonucleotide medicines for nano-rare patients for free for life.

Photo: Erin Decker, director of grantmaking at The Conrad Prebys Foundation

“Nano-rare patients (1 to 30 patients worldwide) have a genetic mutation that is unique to them, and therefore they have few, if any therapeutic options. Today ASO technology and n-Lorem represent the only option for the treatment for many of these nano-rare patients, who are desperate and isolated,” said Stanley Crooke, founder, CEO and chairman of n-Lorem Foundation. “We have more than 40 nano-rare patients at n-Lorem, eight of whom are located in San Diego County. Out of this work, we hope to advance several programs from discovery into development. This work will lead us one step closer to providing a personalized ASO medicine for each nano-rare patient.”

The funding will support n-Lorem’s efforts to discover optimal antisense oligonucleotide (ASO) candidates for several nano-rare patients. Once identified, n-Lorem will conduct preclinical studies necessary to support clinical development for each optimized ASO.

“Through significant investments in medical research during his lifetime, Conrad Prebys helped pave the way for private philanthropy to play a meaningful role in the advancement of the field. The Conrad Prebys Foundation is proud to continue this legacy by supporting n-Lorem Foundation’s unique and vitally important work in rare genetic disease treatment,” said Erin Decker, director of grantmaking at The Conrad Prebys Foundation. “Beyond the significant communities of rare disease patients, n-Lorem’s research has the potential to accelerate important breakthroughs in the biomedical understanding of diseases in general for the benefit of all.”

Author: Rare Daily Staff

Stay Connected

Sign up for updates straight to your inbox.